Abbott Lab Well Poised on Strong EPD, St. Jude Integration

A generic image of a pen, a calculator and sheets
Credit: Shutterstock photo

On May 17, we issued an updated research report on Abbott LaboratoriesABT . The stock currently carries a Zacks Rank #2 (Buy).

Abbott exceeded the Zacks Consensus Estimate on both earnings and sales front in first-quarter 2017. We are particularly optimistic about its strong and consistent Established Pharmaceuticals Division (EPD) and Medical Devices performance.

The company recently noted that, banking on successful execution of its operating model, EPD is well positioned for sustained growth in many of these growing pharmaceutical markets. Particularly, Latin America, China and several markets in Southeast Asia have demonstrated strong growth of late.

Overall, Abbott stands to benefit from the ongoing integration and synergy achievement of St. Jude. The consolidated company has already started to generate positive outcome. The company remains focused on achieving its new product milestones, synergy targets, and financial objectives for 2017.

Abbott is also highly optimistic about the Alere deal. According to the company, the acquisition of Alere will significantly expand its diagnostics presence and leadership in this space. We are also looking forward to the company's plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products.

However, for the last three months, the company traded below the Zacks categorized Large Cap Pharmaceuticals industry. Dull international pediatric business on challenging market conditions in China continues to hamper growth. The stock has lost 2.24% during this period as against 4.81% gain of the broader industry. Also economic problems in Venezuela are expected to remain unresolved in the coming quarters.

Key Picks

Other stocks worth considering in the broader medical sector include Luminex Corporation LMNX , Hologic, Inc. HOLX and Edward Lifesciences, Inc. EW . Luminex sports a Zacks Rank #1 (Strong Buy), while Hologic and Edward Lifesciences carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.

Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 17.0% over the last three months.

Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a solid one-year return of roughly 30.5%.

Edward Lifesciences recorded a stellar EPS growth rate of almost 16% (last three-five years of actual earnings).

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think. See This Ticker Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT): Free Stock Analysis Report

Hologic, Inc. (HOLX): Free Stock Analysis Report

Luminex Corporation (LMNX): Free Stock Analysis Report

Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More